Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Healthpeak Properties Inc V.DOC


Primary Symbol: DOC

Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT). The Company acquires, develops, owns, leases, and manages healthcare real estate across the United States. Its strategy is to invest in and manage real estate focused on healthcare discovery and delivery. It has a diversified portfolio of high-quality healthcare properties across three core asset classes of lab, outpatient medical, and continuing care retirement community (CCRC) real estate. The Company’s segments include Lab, Outpatient medical and CCRC. The lab segment properties contain laboratory and office space, are leased primarily to biotechnology, medical device and pharmaceutical companies, scientific research institutions, government agencies, and other organizations involved in the life science industry. The Outpatient Medical segment includes outpatient medical buildings and hospitals. Outpatient medical buildings typically contain physicians’ offices and examination rooms.


NYSE:DOC - Post by User

Post by retiredcfon Jan 15, 2021 11:07am
292 Views
Post# 32305877

Top Analysts

Top Analysts

2020 was a wild ride for the stock markets.

Against the backdrop of a global pandemic, the markets rallied to new highs, with the TSX rounding out the year at 17,433.40.

At the same time, TipRanks, a financial technology company, tracked the performance of financial analysts who published recommendations throughout 2020, including ratings for the Canadian stock market.

To this end, TipRanks calculated the success rate, or the number of profitable recommendations measured over a three-month period, as well as the average return per rating for the analysts that covered the Canadian market in 2020. What’s more, TipRanks identified the most profitable rating published by each analyst.

In terms of the calculations, we opened a holding for each recommendation, which stayed opened for three months or until the analyst modified their recommendation. A modification could include a rating upgrade or downgrade as well as a price target change.

As for the average return per rating, this was determined using a three-month holding period or until the position was closed. For example, +25% would indicate the average profit over a three-month period.

Here are the results:

Doug Taylor, Canaccord Genuity

Claiming the second spot on TipRanks’ ranking is Canaccord Genuity analyst Doug Taylor

After graduating from Wilfrid Laurier University, Mr. Taylor kicked off his career as an Equity Research Associate at Thomas Weisel Partners, and later joined the team at TD as an Equity Research Analyst. Then, in 2015, he came on as Managing Director and Equity Research Analyst at Canaccord Genuity, covering the healthcare IT sector for the firm.

Over the past year, Mr. Taylor’s recommendations, on average, notched returns of 31.5 per cent. Additionally, his success rate for 2020 comes in at 77 per cent.

Out of all his picks during the course of the year, his “buy” rating on CloudMD Software & Services Inc. , a healthcare services provider that operates through brick-and-mortar clinics and telemedicine as well as pharmacies, was the most profitable. From June 16 through Oct. 16, shares soared 337.1 per cent.

Commenting on the company’s mixed Q3 results, Mr. Taylor noted, “These results reflect only a portion of the asset base the company has assembled through recent M&A activity,” with many acquisitions being finalized after the quarter wrapped up.

Since the beginning of June, CloudMD has announced 10 acquisitions, with the total consideration landing at roughly $57-million, including all cash, shares and potential earnouts. What’s more, Mr. Taylor points out that it has $60-million in cash that it could put towards additional M&A, which could fuel upside to his estimates.

“DOC trades at 9.2 times 2021 EV/Sales but we note that this valuation could be lowered should the company continue to deploy capital on accretive M&A,” Mr. Taylor added.

All of the above prompted Mr. Taylor to maintain a “buy” rating as well as a $3.25 price target on the stock.

<< Previous
Bullboard Posts
Next >>